Gilead makes a $100M bet that Assembly Bio can advance antivirals, tossing lifeline to struggling biotech
Gilead is pouring significant cash into a startup that’s seen several setbacks over the years while promising a hefty helping of biobucks down the road …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
